VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “ Company ”) announces that it will apply to the TSX Venture Exchange (the “ Exchange ”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein. Convertible Debenture Amendments The Company intends to file an application with the Exchange to amend the... Read More